Indication: Hematological Malignancies
A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma
Lymphoma
Drug Study
Principal Investigator: Joseph Maly, M.D.Norton Cancer Institute
Sponsor: ADC Therapeutics SA
Learn more at ClinicalTrials.gov
Email for more information: Heme-NCIResearch@nortonhealthcare.org
